These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10554538)

  • 41. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial.
    Li ZS; Pan X; Zhang WJ; Gong B; Zhi FC; Guo XG; Li PM; Fan ZN; Sun WS; Shen YZ; Ma SR; Xie WF; Chen MH; Li YQ
    Am J Gastroenterol; 2007 Jan; 102(1):46-51. PubMed ID: 17266687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Validity of aprotinin prophylaxis in pancreatitis complications following ERCP].
    Fiocca F; Schietroma M; Colella A; De Santis A; Stabile G; D'Ambrosio G; Greco E; Savino T; Fisicaro V; Pianese G
    G Chir; 1988 May; 9(5):357-8. PubMed ID: 2484805
    [No Abstract]   [Full Text] [Related]  

  • 43. Nafamostat Mesylate is Not Effective in Preventing Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis.
    Matsumoto T; Okuwaki K; Imaizumi H; Kida M; Iwai T; Yamauchi H; Kaneko T; Hasegawa R; Masutani H; Tadehara M; Adachi K; Watanabe M; Kurosu T; Tamaki A; Kikuchi H; Ohno T; Koizumi W
    Dig Dis Sci; 2021 Dec; 66(12):4475-4484. PubMed ID: 33495919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study.
    Prat F; Amaris J; Ducot B; Bocquentin M; Fritsch J; Choury AD; Pelletier G; Buffet C
    Gastrointest Endosc; 2002 Aug; 56(2):202-8. PubMed ID: 12145597
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Utility of bolus somatostatin administration in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a controlled, non-randomized study].
    Vila JJ; Jiménez FJ; Prieto C; Borobio E; Juanmartiñena JF; Borda F
    Gastroenterol Hepatol; 2006 Apr; 29(4):231-6. PubMed ID: 16584693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial.
    Ueki T; Otani K; Kawamoto K; Shimizu A; Fujimura N; Sakaguchi S; Matsui T
    J Gastroenterol; 2007 Feb; 42(2):161-7. PubMed ID: 17351806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prophylactic effect of glyceryl trinitrate on post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized placebo-controlled trial.
    Hao JY; Wu DF; Wang YZ; Gao YX; Lang HP; Zhou WZ
    World J Gastroenterol; 2009 Jan; 15(3):366-8. PubMed ID: 19140238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study.
    Fujishiro H; Adachi K; Imaoka T; Hashimoto T; Kohge N; Moriyama N; Suetsugu H; Kawashima K; Komazawa Y; Ishimura N; Ishihara S; Amano Y; Kinoshita Y
    J Gastroenterol Hepatol; 2006 Jun; 21(6):1065-9. PubMed ID: 16724996
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography.
    Kawaguchi Y; Ogawa M; Omata F; Ito H; Shimosegawa T; Mine T
    World J Gastroenterol; 2012 Apr; 18(14):1635-41. PubMed ID: 22529693
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of octreotide-acetate in preventing pancreatitis-like changes following therapeutic endoscopic retrograde cholangiopancreatography.
    Duvnjak M; Supanc V; Simicević VN; Hrabar D; Troskot B; Smircić-Duvnjak L; Bekavac-Beslin M
    Acta Med Croatica; 1999; 53(3):115-8. PubMed ID: 10705631
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.
    Tsujino T; Isayama H; Nakai Y; Ito Y; Togawa O; Toda N; Arizumi T; Kogure H; Yamamoto K; Mizuno S; Yashima Y; Yagioka H; Sasaki T; Matsubara S; Yamamoto N; Hirano K; Sasahira N; Tada M; Koike K
    J Gastroenterol; 2013 Aug; 48(8):982-8. PubMed ID: 23090004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Prevention of post-ERCP acute pancreatitis with octreotide].
    Baldazzi G; Conti C; Spotti EG; Arisi GP; Scevola M; Gobetti F; Agliardi CM; Galasso P; Bonomi E; Bianchi F
    G Chir; 1994; 15(8-9):359-62. PubMed ID: 7803209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
    Cheng CL; Sherman S; Watkins JL; Barnett J; Freeman M; Geenen J; Ryan M; Parker H; Frakes JT; Fogel EL; Silverman WB; Dua KS; Aliperti G; Yakshe P; Uzer M; Jones W; Goff J; Lazzell-Pannell L; Rashdan A; Temkit M; Lehman GA
    Am J Gastroenterol; 2006 Jan; 101(1):139-47. PubMed ID: 16405547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rectal indomethacin or intravenous gabexate mesylate as prophylaxis for acute pancreatitis post-endoscopic retrograde cholangiopancreatography.
    Guglielmi V; Tutino M; Guerra V; Giorgio P
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5268-5274. PubMed ID: 29228444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural beta-carotene for the prevention of post-ERCP pancreatitis.
    Lavy A; Karban A; Suissa A; Yassin K; Hermesh I; Ben-Amotz A
    Pancreas; 2004 Aug; 29(2):e45-50. PubMed ID: 15257114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
    Sherman S; Alazmi WM; Lehman GA; Geenen JE; Chuttani R; Kozarek RA; Welch WD; Souza S; Pribble J;
    Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The modified pancreatic stent system for prevention of post-ERCP pancreatitis: a case-control study.
    Zhang C; Yang YL; Ma YF; Zhang HW; Li JY; Lin MJ; Shi LJ; Qi CC
    BMC Gastroenterol; 2017 Oct; 17(1):108. PubMed ID: 29047328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors for post-ERCP pancreatitis in high risk patients who have undergone prophylactic pancreatic duct stenting: a multicenter retrospective study.
    Ito K; Fujita N; Kanno A; Matsubayashi H; Okaniwa S; Nakahara K; Suzuki K; Enohara R;
    Intern Med; 2011; 50(24):2927-32. PubMed ID: 22185981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-study protocol MagPEP: a multicentre randomized controlled trial of magnesium sulphate in the prevention of post-ERCP pancreatitis.
    Fluhr G; Mayerle J; Weber E; Aghdassi A; Simon P; Gress T; Seufferlein T; Mössner J; Stallmach A; Rösch T; Müller M; Siegmund B; Büchner-Steudel P; Zuber-Jerger I; Kantowski M; Hoffmeister A; Rosendahl J; Linhart T; Maul J; Czakó L; Hegyi P; Kraft M; Engel G; Kohlmann T; Glitsch A; Pickartz T; Budde C; Nitsche C; Storck K; Lerch MM
    BMC Gastroenterol; 2013 Jan; 13():11. PubMed ID: 23320650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
    Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
    Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.